Irisin as a Predictor of Poor Outcomes in Heart Failure Patients
Author Information
Author(s): Berezina Tetiana A., Berezin Oleksandr O., Novikov Evgen V., Lichtenauer Michael, Berezin Alexander E.
Primary Institution: VitaCenter, Zaporozhye, Ukraine
Hypothesis
Irisin is likely to be the molecule that overcomes the limitations of natriuretic peptides in identifying patients at residual risk in the context of optimal treatment.
Conclusion
Irisin levels of ≤7.2 ng/mL are independent predictors of poor clinical outcomes in heart failure patients with preserved ejection fraction and low NT-proBNP levels.
Supporting Evidence
- 104 out of 337 patients reached the cumulative clinical endpoint.
- Patients with irisin levels > 7.2 ng/mL had better survival rates.
- Age ≥ 64 years and presence of comorbidities were also predictors of poor outcomes.
Takeaway
This study found that low levels of a protein called irisin can help predict if heart failure patients will have bad health outcomes, even if other tests look normal.
Methodology
The study followed 337 heart failure patients for 3 years, measuring various biomarkers and clinical outcomes.
Limitations
The study did not track changes in biomarker levels over time or assess quality of life.
Participant Demographics
Patients were primarily older adults with heart failure and low NT-proBNP levels.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website